Is there a drug for every disease?

Nominee for the European Inventor Award Category Research: Christine van Broeckhoven, Belgium, Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) for her invention: Contributions to neuropathological medicine (on the left). The European Inventor Award, launched by the EPO and EC's DG Enterprise and Industry in 2006, gives inventors the recognition they deserve. And, like every competition, it is an incentive to all other potential winners. It protects ideas and encourages innovation.

Nominee for the European Inventor Award Category Research: Christine van Broeckhoven, Belgium, Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) for her invention: Contributions to neuropathological medicine (on the left). The European Inventor Award, launched by the EPO and EC’s DG Enterprise and Industry in 2006, gives inventors the recognition they deserve.

Pharmaceutical firms in Europe have an awkward relation with their customers. The truth is that their selling prices and product licencing are directly or indirectly controlled by the buyers, that is governments, or government control health insurance schemes, offering almost free health services to citizens. As everybody knows governments are not only able to influence the approval of new drugs, they are also empowered with the ability to set prices by law.With healthcare costs skyrocketing over the past years and the fiscal crisis having engulfed almost all the 27 EU member states, governments have become very careful over their budgets and spending. In view of that, governments have at least two first hand possibilities, to cut down the drug bill.

For one thing officials can reject the use of new and expensive drugs on the grounds that they have no additional cure properties compared to existing formulas or generic medicines. Secondly, governments can set prices by law, or ask the pharmaceutical firms to return a part of their proceeds at the end of the year. As for the licencing procedure it is a common secret that it can be influenced by state officials.

In view of all that pharmaceutical companies are obliged on many occasions to retreat some of their drugs from entire countries, if the governments are not willing to pay what the firms demand. Another dreadful development is that the arbitrary settings of drug cost by governments, leads some times to huge price differences of the same drug, even in neighbouring countries. In this way large incentives for parallel exports are created, to the detriment of the maker.

Greece is an example of all that absurdities in the market of drags.

Greece

This debt stricken and practically bankrupt country has a history of high drug bills. Government spending on medicines skyrocketed within a few years, from 2002 to 2008. In this short time interval, state budget and public health schemes spending on medicines, doubled to €9 billion from less than €5bn. This outrageous development was the outcome of fraudulent behaviour all along the line. Doctors issued hideously expensive prescriptions, patients didn’t mind because they didn’t pay themselves and pharmacists had a guaranteed 30% profit on sales. During the same time period the number of pharmacies almost doubled and today their numbers per 100,000 of population are 60% above Belgium, the country with more pharmacies in the European Union.

As everybody remembers however, towards the end of 2009 Greece found difficulties in honouring its public debt and within months Eurozone had to support Athens, in order this Eurozone country to avoid bankruptcy. From then onwards Greece is under strong pressure to cut down government spending. To a large extend those fiscal deficit reductions are realised through deep cuts on public bills on drugs. Actually the Greek government doesn’t pay at all its drag bills for many months in a row, posing grave liquidity problems to makers, wholesalers and pharmacists.

The Greek authorities however are using more “methods” to cut down the drag bill. Successive Health Ministers had a rough time, trying to expand the use of generics. Expenditure on prototypes was 80% of total, while in Swiss home to many pharmaceutical giants, such generosity is out of question. In any case medicines are not the only bitter pills, Greece should take. A major reorganisation of the country’s health system was long overdue, but the government rushed to economise on the easy target, which is the expenditure on medicines.

Due to continued government inability to tackle the problem in a rational and organised way over the past months, the entire public health system of Greece is in a desperate state, with everybody going on strike and first degree health care and hospitals deep in the red.

Incidentally the abuse of prototype drags is responsible for only a small part of the huge debts the Greek health system accumulates every month. The Greek government owes billions of euros to many Pharmaceutical firms and some of them are threatening to abandon the country altogether and retreat their drags. Unfortunately there is no end to what is wrong with the Greek health system.

Mismanagement and corruption reigned for decades in public hospitals and the first degree health care system of the country, starting from the unholy alliance of doctors and pharmacists, to the exploitation of hospital patients by doctors. It is not clear which direction the whole issue will take, but it is more that certain a lot of things are to change. Probably the public healthcare system will shrink and the private sector will take its place.

But let Greece cure its own diseases and direct this discussion to the powerhouse of pharmaceutical industry, the R&D.

New drags

No need to say, that success in this department is key to survival and growth. Understandably, pharmaceutical firms can secure additional receipts and extra profits only from new drugs, the development and licencing of which though is becoming all the time more complicated and expensive. On top of that research and development of new formulas has become so focused and specialised, that on many occasions it is carried through more successfully by small groups or even one scientist in private laboratories or universities.

As a result major companies with big, expensive and sometimes rigid R&D departments cannot compete with independent researchers. Practice has shown that the solution the large multinationals now prefer is to buy out small research firms rather than develop new drags by themselves. Still however there are great risks and large investments are required.

“To help cope with declining revenue, Pfizer, Eli Lilly & Co., Bristol-Myers and AstraZeneca will probably increase spending on acquisitions beyond their normal budgets because of “deep operating challenges coupled with deep pockets,” Fitch Ratings said last week”, and Bloomberg reported.

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

First 17 “European Universities” selected: a major step towards building a European Education Area

100 years on, UN labour agency mission focussed on growing inequality, says Director-General

Business can be profitable AND drive progress on societal priorities

Cohesion Policy after 2020: preparing the future of EU investments in health

To retire at 65, American millennials need to save almost half their paycheck

UN Chief ‘strongly rejects’ Guatemala decision to expel anti-corruption body

UN agencies call for action to bolster rights of Europe’s stateless children

The world is a book and those who do not travel read only one page

GSMA Mobile 360 in Kuala Lumpur– Digital Societies, in association with The European Sting

What the Fifth Industrial Revolution is and why it matters

Just transition in EU regions: support to people, economy and environment

Happiness apps: how schools are joining the fight for better student mental health

Low productivity jobs continue to drive employment growth

This is why retail is such a sore point in India-US trade relations

Serious concerns over Sahel, require ‘urgent action’: Senior UN Africa official

EU Budget 2019: focus on the young, on migration and innovation

How big data can help us fight climate change faster

Entrepreneurship’s key to success showcased by a serial young entrepreneur

UN Children’s Fund chief condemns ‘horrific’ Kabul bomb attack

EU presses India for a free trade agreement

Former Chilean President Bachelet put forward by UN chief as next High Commissioner for Human Rights

France is bringing back national service

Silicon Valley can do more to achieve the #GlobalGoals

Is Eurozone preparing to abandon austerity and stagnation?

Unemployment and stagnation can tear Eurozone apart if austere policies persist

Lives at risk if wireless technology demands are not held in check: UN weather watchdog

Welfare of transported animals: MEPs urge EU states to do a better job

South Sudan famine threat: UN food security agency in ‘race against time’

How can we make entrepreneurship serve the greater good?

Abu Dhabi is investing $250 million in tech start-ups

EU cross-border payments outside Eurozone: MEPs scrap excessive fees

Restore land to save the planet, boost the economy, says head of UN body combating desertification

COVID-19: Commission provides guidance on EU passenger rights

Africa Forum aims to boost business, reduce costs, help countries trade out of poverty

Teamgum @ TheNextWeb 2014

The global appetite for meat is growing, and it’s harming the planet

All States have ‘primary responsibility’ to protect against hate attacks

End racist discrimination against Afro-European people in the EU

‘Stay at home’ UK tells people as global confirmed cases pass 380,000 – Today’s coronavirus updates

The digital skills gap is widening fast. Here’s how to bridge it

Trump’s Russophiles under investigation, Europe remains ‘en garde’

This Hungarian man quit his job to clean up his favourite river

What’s needed now to fight COVID-19 – Updates from today’s WHO briefing

Endocrine disruptors: A strategy for the future that protects EU citizens and the environment

Youth not prioritised in new Commission

Sudan: top UN official demands cessation of violence and rape against civilians by security forces

MEPs urge the EU to lead the way to net-zero emissions by 2050

Counterfeiters are taking advantage of the pandemic. Here’s how to stop them

Investment, not debt, can kick-start an entrepreneurial Europe

Nearly four million North Koreans in urgent need, as food production slumps by almost 10 per cent

UN rights experts call on Russia to release Ukrainian film-maker whose life is in ‘imminent danger’

Food finally features in the climate debate. Now what?

Terrorist content online: companies to be given just one hour to remove it

Sustainable Infrastructure and Connectivity in the Belt and Road Initiative (BRI): a stimulating China-EU dialogue at European Business Summit 2018

A Sting Exclusive: “Asia-Pacific response to COVID-19 and climate emergency must build a resilient and sustainable future”, by the United Nations Under-Secretary-General

From start-up to scale: This is how governments can accelerate innovation and build inclusive economies

FROM THE FIELD: Enslaved Guatemalan indigenous women wait for reparations

How the world can gear up for the fight against cancer

Mozambique pledging conference hopes to soften devastating blow of back-to-back cyclones

African continent ‘an example of solidarity’ towards migrants and refugees: UN chief

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s